Our groundbreaking and versatile antibody technology harnesses the power of immunotherapy and vaccines by stimulating dendritic cells (DCs).
EnnoDC I Ant-DC40
Humanized V regions (antibody CD40)
Human IgG4 C regions
Antigens from the pathogenic target cells or virus
Anti-CD40
I Versatile Antibody Technology
Our approach combines immunotherapy activation and vaccine specificity with a mAbs fused with a commutable antigen targeting DCs through CD40. The advantage of using these antibodies is that they provide a dual action approach, enhanced specificity and delivering antigens to DCs.
